1 INTRODUCTION     

    1.1    Key Take Aways    
    1.2    Report Description    
    1.3    Markets Covered    
    1.4    Stakeholders    
    1.5    Research Methodology    
        1.5.1    Market Size    
        1.5.2    Market Share    
        1.5.3    Key Data Points From Secondary Sources    
        1.5.4    Key Data Points From Primary Sources

2 Research Methodology
    2.1 Research Methodology Steps
           2.1.1 Research Design
           2.1.2 Secondary and Primary Research Methodology
                     2.1.2.1 Secondary Research
                     2.1.2.2 Primary Research
                     2.1.2.3 Key Industry Insights
           2.1.3 Key Data From Primary Sources
           2.1.4 Key Insights From Primary Sources
           2.1.5 Market Size Estimation Methodology
           2.1.6 Market Data Validation and Triangulation
           2.1.7 Assumptions for the Study

3 Executive Summary
    3.1 Introduction
    3.2 Conclusion

4 Premium Insights
    4.1 Nuclear Medicine/Radiopharmaceuticals: Market Overview
    4.2 Geographic Analysis: Nuclear Medicine Market, By PET Application (2017)
    4.3 Nuclear Medicine Market, By Type (2018 vs 2024)
    4.4 Geographical Snapshot of the Nuclear Medicine Market

5 Market Overview
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                     5.2.1.1 Investments Through Public-Private Partnerships to Modernize Diagnostic Imaging Centers
                     5.2.1.2 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
                     5.2.1.3 Advances in Radiotracers
                     5.2.1.4 Increasing Incidence and Prevalence of Cancer and Cardiac Ailments
           5.2.2 Restraints
                     5.2.2.1 Shorter Half-Life of Radiopharmaceuticals
                     5.2.2.2 High Cost of Nuclear Medicine Equipment
           5.2.3 Opportunities
                     5.2.3.1 High Demand in Emerging Markets
                     5.2.3.2 Upcoming Radioisotopes
                     5.2.3.3 Use of Radiopharmaceuticals in Neurological Applications
           5.2.4 Challenges
                     5.2.4.1 Shutdown of Nuclear Reactors

6 Nuclear Medicine Market, By Type
    6.1 Introduction
    6.2 Diagnostic Nuclear Medicine/Radiopharmaceuticals
           6.2.1 SPECT Radiopharmaceuticals
                     6.2.1.1 Technetium-99m
                     6.2.1.2 Thallium-201
                     6.2.1.3 Gallium-67
                     6.2.1.4 Iodine-123
                     6.2.1.5 Other SPECT Isotopes
           6.2.2 PET Radiopharmaceuticals
                     6.2.2.1 Fluorine-18
                     6.2.2.2 Rubidium-82
                     6.2.2.3 Other PET Isotopes
    6.3 Therapeutic Nuclear Medicine/Radiopharmaceuticals
           6.3.1 Beta Emitters
                     6.3.1.1 Iodine-131
                     6.3.1.2 Yttrium-90
                     6.3.1.3 Samarium-153
                     6.3.1.4 Rhenium-186
                     6.3.1.5 Lutetium-177
                     6.3.1.6 Other Beta Emitters
           6.3.2 Alpha Emitters
                     6.3.2.1 Radium-223
           6.3.3 Brachytherapy Isotopes
                     6.3.3.1 Iodine-125
                     6.3.3.2 Iridium-192
                     6.3.3.3 Palladium-103
                     6.3.3.4 Cesium-131
                     6.3.3.5 Other Brachytherapy Isotopes

7 Nuclear Medicine Market, By Application
    7.1 Introduction
    7.2 Diagnostic Applications
           7.2.1 SPECT Applications
                     7.2.1.1 Cardiology
                     7.2.1.2 Neurology
                     7.2.1.3 Thyroid
                     7.2.1.4 Other SPECT Applications
           7.2.2 PET Applications
                     7.2.2.1 Oncology
                     7.2.2.2 Cardiology
                     7.2.2.3 Neurology
                     7.2.2.4 Other PET Applications
    7.3 Therapeutic Applications
           7.3.1 Thyroid
           7.3.2 Bone Metastasis
           7.3.3 Lymphoma
           7.3.4 Endocrine Tumors
           7.3.5 Other Therapeutic Applications

8 Nuclear Medicine Market, By Procedural Volume
    8.1 Introduction
    8.2 Diagnostic Procedures
           8.2.1 SPECT Radiopharmaceuticals
           8.2.2 PET Radiopharmaceuticals
    8.3 Therapeutic Procedures
           8.3.1 Beta Emitters
           8.3.2 Alpha Emitters
           8.3.3 Brachytherapy Isotopes

9 Global Nuclear Medicine Market, By Region
    9.1 Introduction
    9.2 Diagnostics
           9.2.1 North America
           9.2.2 U.S.
                     9.2.2.1 Domestic Production of Mo-99 in the U.S.
                     9.2.2.2 Approval of New Radiopharmaceuticals By the FDA
           9.2.3 Canada
                     9.2.3.1 Extension of Operations at the Canadian National Research Universal (NRU) Reactor
                     9.2.3.2 Alternative Medical Isotope Technologies in Canada
    9.3 Europe
           9.3.1 Germany
                     9.3.1.1 New Irradiation Facility in Germany
           9.3.2 France
                     9.3.2.1 Shutdown of the French Osiris Nuclear Reactor
           9.3.3 U.K.
                     9.3.3.1 Increasing Adoption of Nuclear Medicine Equipment
           9.3.4 Italy
                     9.3.4.1 Steady Growth in Healthcare Expenditure
           9.3.5 Spain
                     9.3.5.1 Role of the Semnim in Spain
           9.3.6 Rest of Europe (RoE)
                     9.3.6.1 Rapid Rise in the Geriatric Population
    9.4 Asia-Pacific
           9.4.1 Installations of PET Scanners in India
           9.4.2 Investments By the Australian Government
           9.4.3 Initiatives to Promote Health
    9.5 Rest of the World
           9.5.1 Iaea Initiatives in Latam
           9.5.2 Argentina’s Increasing Irradiation Capacity

10 Global Nuclear Medicine Market, By Region
     10.1 Therapeutic Nuclear Medicine Market
               10.1.1 North America
               10.1.2 U.S.
                           10.1.2.1 FDA Approval for Alpha Emitters
                           10.1.2.2 Therapeutic Nuclear Medicine – Alternative Treatment Choice in Oncology
               10.1.3 Canada
                           10.1.3.1 Expertise in Isotope Production
                           10.1.3.2 Government Initiatives to Increase the Number of Nuclear Medicine Treatment Centers
               10.1.4 Europe
               10.1.5 Germany
                           10.1.5.1 Radionuklidtherapeutika — A Research Program Conducted in Germany
               10.1.6 France
                           10.1.6.1 the Firm Project
               10.1.7 U.K.
                           10.1.7.1 “A Voice for Radiotherapy” Initiative in the U.K.
               10.1.8 Italy
                           10.1.8.1 Growing Incidences of Cancer
               10.1.9 Spain
                           10.1.9.1 Rising Demand for Radiotherapeutics
               10.1.10 RoE
                           10.1.10.1 Government and Public–Private Investments
                           10.1.10.2 Research on Cancer in Poland
               10.1.11 Asia-Pacific
                             10.1.11.1 Increasing Aging Population in Japan
                             10.1.11.2 Aging Population and Increasing Cancer Prevalence in China
                             10.1.11.3 Approval of Radium (223ra) Dichloride By the Therapeutic Goods Administration (TGA) in Australia
               10.1.12 Rest of the World (RoW)
                            10.1.12.1 Increase in Cancer Incidences

11 Competitive Landscape
     11.1 Overview
     11.2 Market Share Analysis
               11.2.1 Introduction
               11.2.2 Cardinal Health, Inc.
               11.2.3 Mallinckrodt PLC
               11.2.4 GE Healthcare
               11.2.5 Bayer Healthcare
               11.2.6 Lantheus Medical Imaging, Inc.
     11.3 Competitive Situations and Trends
               11.3.1 Agreements, Partnerships, and Contracts
               11.3.2 Marketing and Promotional Activities
               11.3.3 Expansions
               11.3.4 Acquisitions
               11.3.5 Product Approvals
               11.3.6 Divestments
               11.3.7 Product Launches
               11.3.8 Other Strategies

12 Company Profiles

     12.1 Introduction
     12.2 Cardinal Health, Inc.
     12.3 Mallinckrodt PLC  
     12.4 GE Healthcare (A Fully Owned Subsidiary of General Electric Company)
     12.5 Lantheus Medical Imaging, Inc.
     12.6 Bayer AG
     12.7 Bracco Imaging S.P.A
     12.8 Eczacibasi-Monrol Nuclear Products
     12.9 Nordion, Inc. (A Subsidiary of Sterigenics International LLC.)
     12.10 Advanced Accelerator Applications S.A.
     12.11 IBA Molecular